

Tuesday 1 April 2025

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Thursday 20 March 2025. I am pleased to confirm the following.

How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?

17

How many ovarian cancer patients (any stage) have been treated in the last 3 months with:

Paclitaxel in combination with a platinum-based compound - 25
 Platinum-based therapy alone (cisplatin or carboplatin) - 1
 Bevacizumab in combination with paclitaxel and carboplatin - 12
 Olaparib -2
 Olaparib + Bevacizumab - 0
 Niraparib -6
 Rucaparib -1

Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part

No, we don't currently have any studies open or in set-up.

If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:

Olaparib
 Olaparib + Bevacizumab
 Niraparib
 Other treatments

No data available to pharmacy 0

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Team Lead
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.